Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Emergent BioSolutions Inc.NYSE: EBS

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 40.3% from a year ago

Net receivables stood at $121.6M at the end of Q1 FY2026, down 40.3% from a year earlier and up 44.4% from the prior quarter. Over 3 fiscal years it compounded at -19.1% a year.

Context

  • Net receivables amounted to 9.2% of total assets at the end of Q1 FY2026, down 5.1 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -40.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$121.6M+44.4% QoQ
Last fiscal yearDec 2025
$84.2M-45.5% YoY
Year agoMar 2025
$203.7M-40.3% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.3%——
1 year-45.5%——
3-year CAGR-19.1%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
84.2M USD
Year-over-year change
-45.5%
4-year CAGR
-25.9%

Net Receivables vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -40.3% is the 9th highest of 10, against a peer median of +13.2%.
  • Net receivables amounts to 9.2% of total assets for EBS, versus a peer median of 2.6%.
EBS Competitors
Net Receivables for EBS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ESPREsperion Therapeutics, Inc.Mar 2026$132.35M USD+62.8%+60.8%28.6%
EBSEmergent BioSolutions Inc.Mar 2026$121.6M USD-40.3%-19.1%9.2%
ORGOOrganogenesis Holdings Inc.Mar 2026$116.91M USD+13.2%+34.5%22.5%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$49.95M USD+20.2%+8.7%9.9%
SNDLSNDL Inc.Mar 2026CA$31.91M CAD+7.2%+10.4%2.4%
CMPSCOMPASS Pathways plcMar 2026$15.13M USD-51.7%-0.5%2.8%
AQSTAquestive Therapeutics, Inc.Mar 2026$6.87M USD-34.2%+55.7%4.9%
SIGASIGA Technologies, Inc.Mar 2026$4.5M USD-37.4%-58.4%2.1%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$3.35M USD+74.5%+133.4%0.6%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$1.2M USD+427.8%-16.1%0.5%
PRTAProthena Corporation plcMar 2026$0 USD——0.0%
Peer median (excluding EBS) —+13.2%+10.4%2.6%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents576.3M642.6M111.7M99.5M205.4M
Short-term Investments00000
Net Receivables278.9M159.2M191M154.5M84.2M
Inventory344.5M350.7M328.9M311.7M343.4M
Other Current Assets70.2M57.9M47.9M33M29.5M
Total Current Assets1.27B1.21B679.5M598.7M662.5M
Property, Plant & Equipment (Net)828.4M837M399M270.6M205.4M
Goodwill224.9M218.2M000
Intangible Assets604.6M728.8M566.6M501.5M436.5M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets29.9M171.9M178.1M18.9M14.2M
Total Non-current Assets1.69B1.96B1.14B791M656.1M
Total Assets2.96B3.17B1.82B1.39B1.32B
Account Payables128.9M103.5M112.2M60.9M55.6M
Short-term Debt37.4M963.1M413.7M2.7M0
Tax Payables00000
Deferred Revenue11.7M26.4M000
Other Current Liabilities107.3M48.6M106.8M81.1M76.6M
Total Current Liabilities374M1.23B651.3M162.4M132.2M
Long-term Debt809.4M448.5M446.5M663.7M572.1M
Deferred Tax Liabilities93.3M59.7M47.2M41.7M37.8M
Deferred Revenue (Non-current)4.7M0000
Other Non-current Liabilities40.6M26.7M28.9M29.4M53.9M
Total Non-current Liabilities972.2M549.7M522.6M744.5M663.8M
Total Liabilities1.35B1.78B1.17B906.9M796M
Common Stock100K100K100K100K100K
Retained Earnings950.3M738.7M(21.8M)(212.4M)(159.8M)
Accumulated OCI(16.1M)3.1M(5.7M)(5.2M)(7.5M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.61B1.39B649.3M482.8M522.6M
Total Debt871M1.43B860.2M676.1M572.1M
Net Debt294.7M783.8M748.5M576.6M366.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.